Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2018
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms RISE-M
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.
- 01 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 30 Nov 2018.
- 23 Aug 2018 New trial record